Abstract
Abstract Objective Platinum-based chemotherapy is the first-line treatment for non-small cell lung cancer, but the chemoresistance of tumor cells continues to be a considerable challenge in the management of NSCLCs, leading to recurrence of most patients. CD133 (prominin-1) is a five-transmembrane glycoprotein, and recent evidence suggests that CD133+ cells are the cause of drug resistance and tumor recurrence. In this study, the correlation between cisplatin and CD133+ cells was investigated systematically. Methods Four lung cancer cell lines, including A549, H460, 801D and H1299, were treated with different concentrations of cisplatin. Cell viability was determined by MTT assay. Sphere-forming assay was performed to detect the capability of sphere-forming. CD133+ cells was detected by BD FACScaliber flow cytometer. Results The results showed that cisplatin could increase the number of CD133+ cells in both time- and dose-dependent manner. The enrichment would weaken but the proportion of CD133+ cells was still higher than the basic level as incubation time extended after cisplatin was withdrawn. Compared with adherent culture, the proportion of CD133+ cells was higher when the cells were maintained suspension culture. The proportion of CD133+ cells significantly increased when cisplatin was provided in suspension culture. Conclusion These results revealed that cisplatin induces the enrichment of CD133+ cells and CD133 is a new therapeutic target. Our data partially explained drug resistance to second-line chemotherapy in cisplatin-treated patients with NSCLCs.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call